Steven Lichtman
Stock Analyst at Oppenheimer
(2.95)
# 1,590
Out of 5,031 analysts
71
Total ratings
41.18%
Success rate
12.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Outperform | $44 → $22 | $14.79 | +48.75% | 2 | Sep 8, 2025 | |
| PODD Insulet | Maintains: Outperform | $324 → $365 | $318.59 | +14.57% | 7 | Sep 8, 2025 | |
| BSX Boston Scientific | Upgrades: Outperform | $118 → $125 | $99.24 | +25.96% | 4 | Sep 8, 2025 | |
| DXCM DexCom | Maintains: Outperform | $95 → $102 | $66.60 | +53.15% | 9 | Jul 31, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $101.92 | +32.46% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.47 | +119.38% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $75.11 | +46.45% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $95.78 | -1.86% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $8.24 | +688.83% | 8 | Aug 6, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $16.00 | -31.25% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $11.54 | +3.99% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $81.86 | +6.28% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.58 | +506.06% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $374.42 | -23.08% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $87.17 | +20.45% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $25.03 | +499.28% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $71.97 | +18.10% | 3 | Sep 4, 2020 |
Tandem Diabetes Care
Sep 8, 2025
Maintains: Outperform
Price Target: $44 → $22
Current: $14.79
Upside: +48.75%
Insulet
Sep 8, 2025
Maintains: Outperform
Price Target: $324 → $365
Current: $318.59
Upside: +14.57%
Boston Scientific
Sep 8, 2025
Upgrades: Outperform
Price Target: $118 → $125
Current: $99.24
Upside: +25.96%
DexCom
Jul 31, 2025
Maintains: Outperform
Price Target: $95 → $102
Current: $66.60
Upside: +53.15%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $101.92
Upside: +32.46%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.47
Upside: +119.38%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $75.11
Upside: +46.45%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $95.78
Upside: -1.86%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $8.24
Upside: +688.83%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $16.00
Upside: -31.25%
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $11.54
Upside: +3.99%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $81.86
Upside: +6.28%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.58
Upside: +506.06%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $374.42
Upside: -23.08%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $87.17
Upside: +20.45%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $25.03
Upside: +499.28%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $71.97
Upside: +18.10%